Non-Hodgkin’s lymphoma
What Is Non-Hodgkin’s Lymphoma?
Non Hodgkin lymphoma is the most common hematological malignancy worldwide, representing a diverse group of cancers arising within the immune system rather than a single uniform disease.1
Each year, more than half a million people worldwide are diagnosed with non Hodgkin lymphoma, and the disease accounts for nearly three percent of all cancer diagnoses and deaths globally.1
Non Hodgkin lymphoma is a heterogeneous disease, meaning each of its many subtypes carries distinct biological features, risk factors, and treatment considerations.2
Non Hodgkin lymphoma is the most common hematological malignancy worldwide, a diverse group of cancers of the immune system.
National Center for Biotechnology Information
Symptoms
Common signs and symptoms of non Hodgkin lymphoma include swollen lymph nodes, fever, drenching night sweats, unintentional weight loss, and persistent fatigue.1
Because swollen lymph nodes can result from many far more common and benign conditions, non Hodgkin lymphoma is sometimes not suspected until symptoms have persisted for an extended period.1
Symptom patterns can vary meaningfully depending on the specific lymphoma subtype involved, further underscoring the importance of accurate diagnostic classification.2
Causes
Non Hodgkin lymphoma develops when white blood cells called lymphocytes undergo genetic changes that allow them to grow and divide abnormally, eventually forming tumors within lymph nodes or other tissues.
The best established causal risk factors include immunosuppression and infections such as HIV, hepatitis C, and Epstein Barr virus, all of which can disrupt normal immune regulation.2
Autoimmune diseases are also closely linked to non Hodgkin lymphoma development, with specific subtypes showing strong associations with particular autoimmune conditions.2
Risk Factors
Non Hodgkin lymphoma is more common among men, individuals over sixty five years of age, and those with autoimmune disease or a family history of blood related cancers.2
Marginal zone lymphoma is strongly associated with Sjogren syndrome and Hashimoto thyroiditis, while peripheral T cell lymphoma shows the strongest association with celiac disease among recognized subtype specific risk factors.2
Prior radiation treatment, obesity, and smoking are most strongly associated with diffuse large B cell lymphoma, while occupational exposures among farm workers and painters increase risk across most common subtypes.2
Complications
Diffuse large B cell lymphoma and follicular lymphoma together account for approximately thirty and twenty percent of all non Hodgkin lymphoma cases respectively, making them the two most common subtypes encountered clinically.2
Less common subtypes, including Burkitt lymphoma, mantle cell lymphoma, and peripheral T cell lymphoma, each carry their own distinct clinical behavior and prognosis, ranging from highly aggressive to relatively indolent disease courses.2
For patients with relapsed or refractory disease following standard treatment, outcomes have historically been challenging, driving significant interest in newer immune based treatment approaches.3
Treatment
Chimeric antigen receptor T cell therapy, commonly known as CAR T cell therapy, has substantially improved outcomes for patients with relapsed or refractory diffuse large B cell lymphoma compared to standard chemotherapy regimens.3
Clinical trial data show strong results with this approach, with objective response rates reaching as high as eighty two percent and complete response rates around fifty four percent in certain studies of relapsed disease.4
While highly effective, CAR T cell therapy carries a distinct side effect profile, including notable rates of significant anemia and low platelet counts, requiring careful patient selection and monitoring.4
Prevention
Because non Hodgkin lymphoma arises from a complex combination of genetic, infectious, and immune related factors, there is no single reliable way to prevent the disease.
Managing chronic infections such as hepatitis C and HIV, when present, may help reduce associated lymphoma risk over time.2
Avoiding tobacco use and maintaining a healthy body weight may also offer modest risk reduction, particularly with respect to diffuse large B cell lymphoma specifically.2
Why Visual Communication Matters for Non-Hodgkin’s Lymphoma
Explaining the wide diversity of non Hodgkin lymphoma subtypes, along with newer treatments like CAR T cell therapy, requires visuals that clarify both disease biology and complex treatment mechanisms.
Pharmaceutical companies, hematology oncology practices, and patient education organizations rely on precise illustration and animation to explain non Hodgkin lymphoma diagnosis and treatment.
- Illustrating lymphocyte biology and malignant transformation
- Animating the mechanism of action of CAR T cell therapy
- Explaining differences between major non Hodgkin lymphoma subtypes
- Visualizing lymph node involvement and disease staging
- Supporting patient education on symptom recognition and treatment options
- Creating training materials for hematology oncology clinicians
How Biotic Artlab Supports Non-Hodgkin’s Lymphoma Communication
We work with pharmaceutical companies, hematology oncology practices, and research organizations to create scientifically accurate visuals that make non Hodgkin lymphoma easier to understand.
- Custom 3D animations of lymphocyte biology and lymphoma development
- Detailed illustrations of CAR T cell therapy mechanisms of action
- Visualizations comparing major non Hodgkin lymphoma subtypes
- Patient facing materials on diagnosis, staging, and treatment options
- Clinical training content for hematology oncology teams
- Conference presentations and marketing visuals for lymphoma research audiences
Frequently Asked Questions
What is non-Hodgkin’s lymphoma?
It is the most common hematological malignancy worldwide, representing a diverse group of cancers arising within the immune system.1
What are common symptoms?
Swollen lymph nodes, fever, night sweats, weight loss, and fatigue are common presenting symptoms.1
What are the most common subtypes?
Diffuse large B cell lymphoma and follicular lymphoma are the two most common subtypes, together accounting for about half of all cases.2
What causes non-Hodgkin’s lymphoma?
Immunosuppression, certain infections, and autoimmune diseases are among the best established causal risk factors.2
What is CAR T cell therapy?
It is an immune based treatment that has significantly improved outcomes for patients with relapsed or refractory diffuse large B cell lymphoma.3
Can non-Hodgkin’s lymphoma be prevented?
There is no single reliable prevention method, though managing chronic infections and avoiding tobacco use may help reduce risk.2
Have a Project in Mind? Contact Us.
If you are developing patient education materials, clinical training content, or marketing visuals related to non Hodgkin lymphoma, our team can help translate the science into visuals that are both accurate and easy to understand. Contact us at info@biotic-artlab.com or get in touch through our contact form to discuss your project.
References
- National Center for Biotechnology Information. Epidemiology of Non-Hodgkin’s Lymphoma.
- National Cancer Institute. Risk Factors Identified for Certain Lymphoma Subtypes.
- National Center for Biotechnology Information. CAR T Cell Therapy in Diffuse Large B Cell Lymphoma, Hype and Hope.
- National Center for Biotechnology Information. Efficacy and Safety of Second Generation CAR T Cell Therapy in Diffuse Large B Cell Lymphoma.
Disclaimer: This page provides general educational information and is not a substitute for diagnosis, treatment, or individualized advice from a qualified healthcare professional.